IDEXX Laboratories Announces Third Quarter Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/21/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- Fed: Nine Of 18 FOMC Participants Pencil In 2026 Rate Hike
- Delta Air Lines (DAL) Raises Quarterly Dividend 14.7% to $0.2150; 1% Yield
- ICC sets July 24 vote on whether to remove chief prosecutor Karim Khan, WSJ reports
IDEXX Labs (IDXX) Tops Q3 EPS by 8c; Raises FY18 EPS Outlook, Maintains FY18 Revenue Guidance, Offers Prelim. FY19 EPS/Revenue Views
November 1, 2018 6:41 AM EDT(Updated - November 1, 2018 6:56 AM EDT)
(Update corrects consensus revenue figure)
IDEXX Labs (NASDAQ: IDXX) reported Q3 EPS of $1.05, $0.08 better than the analyst estimate of $0.97. Revenue for the quarter came in at $545.45 million versus the consensus estimate of $545.49 million.
Reports revenue growth of 11% on a reported basis and 12% on an organic basis, driven by CAG Diagnostics recurring revenue growth of 12% reported and 13% organicDelivers EPS of $1.05, a 33% increase year-over-year on a reported basis or 39% on a comparable constant currency basisRefines 2018 reported revenue guidance to $2,205 billion - $2,215... More